FDA OKs expanded label for Senseonics’ Eversense Continuous Glucose Monitor

The FDA has approved Senseonics’ (SENS -2.7%) supplemental marketing application to expand the label of its Eversense Continuous Glucose Monitoring (CGM) System to include “replacement of fingerstick blood glucose testing for diabetes treatment decisions.”

https://seekingalpha.com/news/3469651-fda-oks-expanded-label-senseonics-eversense-cgm